Research Article

Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases

Table 3

ADR manifestations of DHI.

Systems/organsFrequencyConstituent ratio (%)Manifestations (number of cases)

Skin and its appendages4730.13Pruritus (23), rash (19), sweating (3), and clammy skin (2)
The central and peripheral nervous system damage3421.79Dizziness (17), headache (16), and tics (1)
Extracardiac vascular damage2516.03Superficial phlebitis (12), flushing (9), allergic purpura (1), vasodilation (2), and eye hemorrhage (1)
Systemic damage127.69Chills (6), high fever (2), fever (1), periorbital edema (1), faintness (1), and chest pain (1)
Heart rate and rhythm disorders106.41Palpitations (10)
Neurological disorders106.41Breathlessness (7), anxiousness (3)
Gastrointestinal system damage95.77Nausea (6), flatulence (2), and vomiting (1)
General damages to the cardiovascular system42.56Cyanosis (2), hypotension (1), and hypertension (1)
Medication site damage21.28Local numbness (2)
Respiratory system damage10.64Dyspnea (1)
Musculoskeletal system damage10.64Joint disease (1)
Auditory and vestibular dysfunction10.64Tinnitus (1)
Total156100.00ā€‰